

**AMENDMENTS TO THE CLAIMS**

*This listing of claims replaces all prior versions of listing of claims, and listing of claims in the application.*

1.-20. (Cancelled)

21. (Currently Amended) A method for detecting IgA or IgG anti-transglutaminase antibodies in liquid samples, the method comprising:

- a) providing a system comprising:
  - (i) an inert porous support wherein tissue transglutaminase antigen conjugated to a colored substance is deposited and dried, and wherein the support allows release and laminar flow of the conjugated antigen when contacted with a liquid sample; and
  - (ii) a membrane comprising a reactive zone which comprises immobilized tissue transglutaminase antigen;
- b) obtaining a liquid sample from a human;
- c) adding the liquid sample to the inert porous support containing tissue transglutaminase antigen conjugated to a colored substance, wherein the conjugated antigen and/or immunocomplexes formed between antibodies in the sample and the conjugated antigen migrate to the reactive zone by laminar flow; and
- d) detecting any binding reaction of between the immunocomplexes formed ~~described~~ in step c) with the immobilized antigen, wherein binding of the ~~presence of the reaction~~ immunocomplexes with the immobilized antigen in the reactive zone indicates the presence of IgA or IgG anti-transglutaminase antibodies in the sample.

22. (Currently Amended) The method according to claim 21, wherein the membrane further comprises a control zone, wherein the control zone comprises a control reagent ~~that which reacts~~ binds with the conjugated antigen.

23. (Currently Amended) The method according to claim 22, wherein the method further comprises detecting binding ~~reaction~~ of the conjugated antigen with the control reagent, wherein binding ~~presence of the reaction~~ of the conjugated antigen with the control reagent indicates performance of the method.

24. (Previously Presented) The method according to claim 21, wherein the sample is blood.

25. (Previously Presented) The method according to claim 21, wherein the sample is plasma.

26. (Previously Presented) The method according to claim 21, wherein the sample is serum.